Volitionrx limited: revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Henderson, nev. , april 29, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announces that president and group chief executive officer, cameron reynolds, has issued a shareholder letter providing a business update.

VNRX Ratings Summary

VNRX Quant Ranking